XNCR — Xencor, Inc.

Is XNCR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Xencor, Inc. (XNCR) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $34.50. The rating moved from Neutral to Strong Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Xencor is a platform‑driven biopharma with multiple clinical assets and external collaborations that provide validation and funding. Near‑term clinical readouts and partnership milestones are the primary upside drivers, while a strong technology platform supports longer‑term optionality. The company remains exposed to typical small‑cap biotech risks — trial outcomes, financing needs and competition — but current valuation and sector flow dynamics leave room for meaningful upside if upcoming data are favorable.

Key factors

  • Proprietary XmAb Fc‑engineering platform that supports differentiated monoclonal and bispecific programs across oncology and immunology
  • Multiple clinical‑stage programs with potential near‑term readouts that could materially re‑rate the equity
  • Strategic collaborations with larger pharmaceutical partners that provide validation and non‑dilutive funding for development
  • Relative attractiveness to growth‑oriented investors amid selective sector support for biotech and specialty pharma
  • Reasonable valuation vs. later‑stage peers, offering asymmetric upside if clinical/data catalysts succeed

Risks

  • Clinical trial setbacks or negative safety/efficacy readouts for lead programs that would materially impact valuation
  • High cash burn and the potential need to raise capital under dilutive terms if partnerships or milestone payments are insufficient
  • Intensifying competition from larger biologics players and next‑generation modalities that could erode long‑term market share
  • Regulatory or reimbursement pressures that reduce pricing power or slow commercialization timelines
  • Macro volatility and a pullback in risk appetite for small‑cap biotech, which can exacerbate share price declines independent of fundamentals
  • Partner or licensing disruptions (terminations, adverse renegotiations) that could delay programs or remove expected funding

See today's live rating, score and targets

Members see the live hourly rating for XNCR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.